The diabetes medicine market in Australia showed significant growth from 2013 to 2023, with sales climbing from $573.4 million to $930.6 million in 2023. The most dynamic increase was seen between 2020 and 2021, with a year-on-year growth of 22.87%. The compound annual growth rate (CAGR) over the last five years (2018-2023) stood at a robust 10.77%, illustrating a strong upward trend.
The forecasted data from 2024 to 2028 reveals continued growth, albeit at a slower pace, with an anticipated CAGR of 3.1%. Expected sales are projected to reach $1,170 million by 2028, reflecting an overall 16.51% growth over five years.
Future trends to watch for include innovations in diabetes treatment, increasing incidence rates of diabetes, and growing awareness and adoption of advanced therapeutic solutions. Additionally, policy changes and potential market entry by new players could influence the market dynamics significantly.
